Head & Neck Cancer
Conditions
Brief summary
This study will be focused on HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016.
Interventions
OTHERNon-Interventional
Non-Interventional
Sponsors
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HNC or undefined histology (not otherwise specified \[NOS\]) HNC diagnosis from 01-Jan-2013 to 30-Sep-2016 using Japanese disease code * Age 18 years or older at initial diagnosis of HNC regardless of staging
Exclusion criteria
* Diagnosis of another malignancy on or before the initial diagnosis of HNC with the exception of non-melanoma skin cancer and metastatic cancer * Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients receiving radiotherapy as anti-cancer treatment | Approximately 45 months |
| Proportion of patients receiving surgery as anti-cancer treatment | Approximately 45 months |
| Proportion of patients receiving chemotherapy as anti-cancer treatment | Approximately 45 months |
| Proportion of patients receiving targeted therapy as anti-cancer treatment | Approximately 45 months |
| Proportion of patients receiving supportive care as anti-cancer treatment | Approximately 45 months |
| Distribution of Treatment History in Head and Neck Cancer (HNC) patients | Approximately 45 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of withdrawals due to AEs | Approximately 45 months | — |
| Number of treatment-limiting adverse events (AEs) | Approximately 45 months | Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies |
| Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC | At Baseline | — |
| Distribution of overall survival (OS) by age | Approximately 45 months | — |
| Distribution of overall survival (OS) by gender | Approximately 45 months | — |
| Distribution of overall survival (OS) by stage | Approximately 45 months | — |
| Distribution of overall survival (OS) by tumor site | Approximately 45 months | — |
| Distribution of overall survival (OS) by treatment regimen | Approximately 45 months | — |
Countries
Japan
Outcome results
None listed